Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multiple Hacking Risks Found In Another Infusion Pump

Executive Summary

After a hacker brought the issue to the attention of Smiths Medical, the company engaged US FDA and the Department of Homeland Security, which alerted users that Smith's Medfusion 4000 wireless syringe infusion pumps are at risk from multiple cybersecurity vulnerabilities.

Advertisement

Related Content

Despite US FDA Alert, Abbott-Muddy Waters Lawsuit Continues
Former FBI Cyber Chief Urges More Proactive Approach to Cybersecurity
Security Firm Confirms 'Petya' Has Affected Medical Devices
WannaCry Cybersecurity Alert Shows Medtech Software Must Look Beyond Quick Fixes
FDA Recommends Security Patch For St. Jude Wireless Cardiac Devices
'Sharing' Organizations Stay In Final Post-Market Cybersecurity Guidance
J&J, Hacker Work Together To Fix Insulin Pump Vulnerability
St. Jude Hacking-Risk Allegations: US FDA Continues Assessment, As Firm Files Lawsuit
FDA Warns Of Hacking Threat From Hospira's Symbiq

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT121472

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel